NEW YORK (TheStreet) -- Sequenom, Inc.
(SQNM - Get Report) shares finished trading Monday up 9.1% to $3.34 following news that the company gained pre-market FDA clearance for its IMPACT genotyping test.
The noninvasive prenatel test analyzes chromosonal material in cell free DNA for pregnant women at an increased risk for fetal chromosonal abnormalities.
The San Diego-based company formed a licencing agreement with Quest Diagnostics (DGX - Get Report) -- expected to make the test available by the third quarter-- to expand patient access to the test.
Must Read: Warren Buffett's 25 Favorite Stocks